LakeShore Biopharma CoLSBCF Days Payable is 206.63 as of Mar. 2025, which is 52% above its 10-year median of 135.54. The stock has 5 warning signs investors should review. Among 708 Biotechnology companies, LakeShore Biopharma Co ranks better than 61.3% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSBCF vs ACUT, PPCB, ENSC: Days Payable Comparison
For the Biotechnology subindustry, LakeShore Biopharma Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Days Payable distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
LakeShore Biopharma Co's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LakeShore Biopharma Co (LSBCF) has a Days Payable of 206.63 as of Mar. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on LakeShore Biopharma Co and its competitors. This is 52% above median its historical median of 135.54. Over the past decade, LakeShore Biopharma Co's Days Payable has ranged from 72.92 to 235.46. According to the industry distribution chart, LakeShore Biopharma Co ranks #274 out of 708 companies in the Biotechnology industry, placing it in the top 38.7%.
Is LakeShore Biopharma Co's Days Payable too high?
LakeShore Biopharma Co's current Days Payable of 206.63 is 52% above median its 10-year median of 135.54. Over the past 10 years, this metric has ranged from a low of 72.92 to a high of 235.46. The Biotechnology industry median Days Payable is 113.56. LakeShore Biopharma Co's value of 206.63 is 82% above this industry median. Based on the distribution chart, LakeShore Biopharma Co ranks #274 out of 708 companies in the Biotechnology industry, which is above the industry midpoint.
How does LakeShore Biopharma Co's Days Payable compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #274 out of 708 companies for Days Payable. This puts LakeShore Biopharma Co in the upper half of its industry. The industry median Days Payable is 113.56. LakeShore Biopharma Co's value of 206.63 is 82% above this benchmark. Historically, LakeShore Biopharma Co's own Days Payable has ranged from 72.92 to 235.46 over the past decade. While the company's 10-year median is 135.54 vs. the industry median of 113.56, LakeShore Biopharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LakeShore Biopharma Co's current Days Payable of 206.63 is 82% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on LakeShore Biopharma Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Days Payable is 206.63, which is 52% above median its own 10-year median of 135.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Days Payable of 206.63. The current Days Payable is 206.63, which is 52% above median its 10-year median of 135.54 and 82% above the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Days Payable is 206.63 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 